Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATDC in highly sensitized kidney transplant recipients
NCT06852625Phase 1Not yet recruiting
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- May 2025
- Primary completion
- Mar 2028
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous tolerogenic dendritic cells in kidney transplant rejection, sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Side effects of ATDC cell product at Day 3. Planned start May 2025; status: not yet recruiting.
02
Drugs
autologous tolerogenic dendritic cells
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT06852625.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06852625.